Early Targeted Antibiotic Therapy in Patients With Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the efficacy of early targeted antibiotic therapy in patients with sepsis and septic shock using the new biomarker Sirtuin 1 and PCR for bacterial resistance detection.

The primary outcome is change in SOFA score (ΔSOFA) which will be calculated by subtracting the final SOFA score and sirtuin 1 level at 5 days from the corresponding initial value at enrollment.

Secondary outcomes included mortality rates, ventilator free days and length of icu stay.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Red Cell Distribution Width and Lactate Albumin Ratio as Prognostic Markers for Mortality in Sepsis and Septic Shock

NCT05921825

Morality Sepsis Septic Shock

UNKNOWN

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

NCT05911711

Sepsis

UNKNOWN

Venous to Arterial Carbon Dioxide Difference (P₍ᵥ-ₐ₎CO₂): Predictor of Septic Patient Prognosis Depending on the ScvO₂

NCT03292120

Septic Shock

COMPLETED NA

Prognostic Evaluation Of Severe Sepsis And Septic Shock. Procalcitonin Versus Delta Sofa

NCT01841190

Severe Sepsis Septic Shock

UNKNOWN

CRP Versus PCT as Bio-markers for Sepsis and in Guiding Antibiotics in Critically Ill Patients

NCT04049565

Sepsis Morality

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* A prospective, single-center, open labeled, randomized interventional study
* Patients will be recruited from a private hospital in Alexandria
* Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University
* Fourty eight critically ill patients, with sepsis and septic shock according to the 2016 third international consensus definitions, will be included
* Patients with risk for Carbapenemase producing organisms:

* Use of broad spectrum cephalosporins and/or carbapenems within the past three months
* Polytrauma
* Diabetes
* Malignancy
* Organ transplantation
* Mechanical ventilation
* Indwelling urinary or venous catheters
* Overall poor functional status or severe illness
* Residence in a long-term care facility(18-28).
* The baseline characteristics of the patients will be collected at the time of enrollment. The collected data included age, sex, ratio of septic shock to sepsis, ratio of ventilated to non-ventilated patients, source of infection, vital signs, laboratory data, arterial blood gas (ABG), APACHE II score, Glasgow Coma Scale score, and SOFA scores. The level of Procalcitonin (PCT) and Sirtuin-1 will also be measured at this time(29).
* Patients will be randomly allocated to antibiotic regimen guided by conventional culture technique (n=24) or targeted antibiotics therapy guided by resistance genotyping (n=24) (29, 30).
* Levels of Sirtuin1 will be detected using ELISA kits as prescribed by manufacturer.
* Traditional diagnostic microbiology techniques relying on the growth of organisms on appropriate culture media (Control group).
* Qualitative Multiplex pcr test will be used for rapid detection of carbapenemases genes (Intervention group)
* Statistical tests appropriate to the study will be conducted to evaluate significance of results
* Results, conclusion, discussion and recommendations will be given.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients will be randomly allocated to antibiotic regimen guided by conventional culture technique (n=24) or targeted antibiotics therapy guided by resistance genotyping (n=24)

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

antibiotic regimen guided by conventional culture technique (n=24)

Group Type NO_INTERVENTION

No interventions assigned to this group

Group B

targeted antibiotics therapy guided by resistance genotyping (n=24)

Group Type EXPERIMENTAL

targeted antibiotics therapy

Intervention Type OTHER

targeted antibiotics therapy guided by resistance genotyping (n=24)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

targeted antibiotics therapy

targeted antibiotics therapy guided by resistance genotyping (n=24)

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

genotyping

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients 18 years or older
2. A definite diagnosis of sepsis or septic shock according to the definition of the 2016 SCCM/ESICM task force.
3. Patients at risk for carbapenemase producing organisms

Exclusion Criteria

1. Pregnant and lactating women
2. hematological disorders (e.g., leukemia, myelodysplastic syndrome, neoplastic metastases to bone marrow),
3. life-threatening diseases (e.g., malignant solid tumors), acquired immunodeficiency syndrome.
4. Lethal traumatic injury
5. Acute Physiologic Assessment and Chronic Health Evaluation II (APACHE II) score ≥34 (due to high predicted mortality of 80%)
6. Primary fungal or viral infections

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No